Abstract
Respiratory syncytial virus (RSV) is a potential cause of serious morbidity and even mortality among children undergoing hematopoietic SCT (HSCT). Contrary to the available information regarding the aerosolized formulation of ribavirin, there is a paucity of published studies using i.v. ribavirin in adults, and very few single reports on pediatric patients. Aerosolized drug administration has been limited by potential toxicity and special air-flow requirements. In this regard, i.v. ribavirin could prevent these disadvantages, but its efficacy and safety remain controversial in the pediatric HSCT setting. The present study describes the outcome of six pediatric patients undergoing HSCT with nine episodes of proven RSV. Four episodes corresponded to lower respiratory tract infection (LRTI) and five presented with upper respiratory tract infection (URTI). All LRTI patients showed favorable clinical responses, with 100% survival and no progression to LRTI in the remaining five URTI. No side effects were documented during ribavirin administration. We conclude that ribavirin was well tolerated intravenously, without associated side effects, and was effective in the treatment of RSV in this limited number of pediatric HSCT patients. The role and efficacy of i.v. ribavirin needs to be further clarified by prospective controlled trials in pediatric populations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Small TN, Casson A, Malak SF, Boulad F, Kiehn TE, Stiles J et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 321–327.
Raboni SM, Nogueira MB, Tsuchiya LR, Takahashi GA, Pereira LA, Pasquini R et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation 2003; 76: 142–146.
Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545–1555.
Langley GF, Anderson LJ . Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J 2011; 30: 510–517.
Riner A, Chan-Tack KM, Murray JS . Intravenous ribavirin--review of the FDA’s Emergency Investigational New Drug Database (1997-2008) and literature review. Postgrad Med 2009; 121: 139–146.
Shah JN, Chemaly RF . Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117: 2755–2763.
Ochoa Sangrador C, González de Dios J . Consensus conference on acute bronchiolitis (II): epidemiology of acute bronchiolitis. Review of the scientific evidence. An Pediatr (Barc) 2010; 72: 284.e1–284.e23.
European group for Blood and Marrow Transplantation (EBMT). European conference on infections and leukemia (ECIL), Available from www.ebmt.org/Contents/Resources/Library/ECIL/Pages/ECIL.aspx (accessed on 6 February 2012).
Khanna N, Widmer AF, Decker M, Steffen I, Halter J, Heim D et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008; 46: 402–412.
Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001; 28: 479–484.
Ventre K, Randolph A . Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2010 CD000181.
Fuller HL, Del Mar CB . Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev 2010 CD004883.
Anaissie EJ, Mahfouz TH, Aslan T, Pouli A, Desikan R, Fassas A et al. The natural history of respiratory syncytial virus infections in cancer and transplant patients: implications for management. Blood 2004; 103: 1611–1617.
Sparrelid E, Ljungman P, Ekelöf-Andström E, Aschan J, Ringdén O, Winiarski J et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 1997; 19: 905–908.
Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P . Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother 1999; 43: 2451–2456.
Schleuning M, Buxbaum-Conradi H, Jäger G, Kolb HJ . Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell transplants. Hematol J 2004; 5: 135–144.
Serranti D, Buonsenso D, Ceccarelli M, Gargiullo L, Ranno O, Valentini P . Pediatric hepatitis C infection: to treat or not to treat...what's the best for the child? Eur Rev Med Pharmacol Sci 2011; 15: 1057–1067.
Anak S, Atay D, Unuvar A, Garipardic M, Agaoglu L, Ozturk G et al. Respiratory syncytial virus infection outbreak among pediatric patients with oncologic diseases and/or BMT. Pediatric Pulmonology 2010; 45: 307–311.
McCarthy AJ, Kingman HM, Kelly C, Taylor GS, Caul EO, Grier D et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. Bone Marrow Transplant 1999; 24: 1315–1322.
DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH . Respiratory syncitial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation – a compassionate use experience. Bone Marrow Transplant 2000; 25: 161–165.
Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramil O . Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediat Infect Dis J 2007; 26: 1089–1093.
The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531–537.
Nair H, Verma VR, Theodoratou E, Zgaga L, Huda T, Simões EA et al. An evaluation of the emerging interventions against respiratory syncytial virus (RSV)-associated acute lower respiratory infections in children. BMC Public Health 2011; 11 (Suppl 3): S30.
Vettenranta K, Ukkonen P, Saarinen UM . RSV infection complicating the therapy of pediatric malignancies: report of six cases. Med Pediatr Oncol 1996; 26: 261–263.
Bredius RG, Templeton KE, Scheltinga SA, Claas EC, Kroes AC, Vossen JM . Prospective study of respiratory viral infections in pediatric hemopoietic stem cell transplantation patients. Pediatr Infect Dis J 2004; 23: 518–522.
Avetisyan G, Mattsson J, Sparrelid E, Ljungman P . Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. Transplantation 2009; 88: 1222–1226.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Molinos-Quintana, A., Pérez-de Soto, C., Gómez-Rosa, M. et al. Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients. Bone Marrow Transplant 48, 265–268 (2013). https://doi.org/10.1038/bmt.2012.134
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.134
Keywords
This article is cited by
-
Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children
Infectious Diseases and Therapy (2018)